Amgen company is seeking to defend its osteoporosis franchise with UCB-partnered Evenity (romosozumab), an anti-sclerostin antibody that was approved for postmenopausal osteoporosis in 2019 and ...

The trio includes two bone-building bispecific antibodies – sclerostin and DKK1-targeting AGA2118 and AGA2115 for osteoporosis and brittle bone disease (osteogenesis imperfecta), respectively ...

The development of precise and efficient delivery systems is pivotal for advancing CRISPR/Cas9 gene-editing technologies, particularly for therapeutic applications. Engineered metal–organic frameworks ...

2162.HK Keymed Biosciences Inc.